CoviSafe is a rapid antigen test that can provide results in 15 minutes. Credit: Ewa Urban / Pixabay.

Therma Bright has created a new venture called Torion Biosciences to develop, license, and commercialise a rapid antigen test, CoviSafe, for screening individuals infected or suspected of exposure to Covid-19 virus.

The company will have 50% control over Torion while the remaining 50% will be owned by others, including veteran biotech executives as the primary shareholders of the new venture.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Furthermore, Therma Bright ended its co-development deal with Orpheus Medica and Torion will hold discussions with key personnel from Orpheus, depending on the needs.

Currently, Torion is in late-stage discussions to buy a series of biological candidates as primary reagents for CoviSafe.

Developed as a point-of-care cassette, CoviSafe is a rapid antigen test that does not require lab instruments or specialised lab personnel to be carried out.

The device uses lateral flow technology to detect the presence of the Covid-19 virus in saliva or other swab samples, including upper respiratory samples, and can provide results in 15 minutes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CoviSafe is developed for use at point-of-care settings such as long-term care facilities, schools, or even at home. It will be progressed into patient sample validation, and later, on to clinical studies with the newly acquired biological molecules.

nanoComposix will carry out CoviSafe product development.

Therma Bright will seek Food and Drug Administration (FDA), Health Canada, and the CE mark for fast track or expedited approval for CoviSafe to test symptomatic patients.

Therma Bright CEO Rob Fia said: “By creating Torion, Therma Bright will own a significant percentage of the venture and the future commercial sales of CoviSafe.

“Our capacity, through our partners, will enable us to manufacture pilot test kits for feasibility and research purposes very quickly.”